Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürstenwalde – page 79

1 727 clinical trials in Fürstenwalde, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürstenwalde at a glance
1 727
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 727 trials in Fürstenwalde

Open in trial search

Study of Astegolimab Treatment in Patients with Chronic Obstructive Pulmonary Disease (COPD) to Reduce Disease Flare-ups

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Astegolimab
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Study on Bowel Urgency in Adults with Moderate to Severe Ulcerative Colitis Treated with Mirikizumab

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Mirikizumab
  • Sponsor:Eli Lilly & Co.

Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vixarelimab
  • Sponsor:Genentech Inc.

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of DC-806 for Adults with Moderate to Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DC-806
  • Sponsor:DICE Therapeutics Inc.

Arthralgia

Not recruiting

Study on the Effects and Safety of ODM-111 and Paracetamol for Chronic Knee Pain in Osteoarthritis Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ODM-111
  • Sponsor:Orion Corporation

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Psoriatic arthropathy

Not recruiting

Study on the Effectiveness and Safety of Bimekizumab and Risankizumab in Adults with Active Psoriatic Arthritis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on Long-Term Safety and Effectiveness of Bimekizumab for Adults with Active Axial Spondyloarthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

A Study Testing VX-407 in Patients with Autosomal Dominant Polycystic Kidney Disease Who Have Specific PKD1 Gene Changes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:VX-407
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on the Effects of Maplirpacept, Glofitamab, and Obinutuzumab in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma Not Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürstenwalde

What the registry says about research in the country

01 Respiratory Tract Diseases

Clinical research in Fürstenwalde Spree is focused on respiratory tract diseases, with all active studies centered on asthma and its more severe forms. These trials are looking at new treatment options, safety, and signs of better disease control for people with difficult-to-manage asthma.

  • Asthma and uncontrolled asthma
  • Severe eosinophilic asthma and eosinophilic phenotype
  • Moderate to severe controlled asthma under current guideline-based care
  • Testing new therapies and comparing them with existing treatments

The research includes studies of inhaled and biologic approaches, with an emphasis on improving symptom control, evaluating long-term safety, and measuring airway inflammation markers.

02 Asthma Treatment Safety and Tolerability

One part of the local trial landscape examines how well new asthma treatments are tolerated, especially in people already living with persistent disease. These studies help determine whether emerging options can offer benefits while remaining safe for everyday use.

  • Asthma treatment safety
  • Comparing different inhaled therapy formulations
  • Assessing long-term safety in ongoing care

This work supports clearer decisions about whether new therapies can be used comfortably and reliably in routine respiratory medicine.

03 Severe Eosinophilic Asthma

Several studies are dedicated to severe eosinophilic asthma, a more advanced form of asthma linked to ongoing inflammation. The goal is to see whether newer biologic treatments can improve control for patients who have already responded to specialized care.

  • Severe eosinophilic asthma
  • Evaluating biologic treatments for better disease control
  • Studying patients who benefited from prior anti-IL-5 or anti-IL-5R therapy

These trials aim to refine treatment choices for people with persistent eosinophilic airway inflammation and ongoing symptoms.

04 Biologic Therapies for Asthma

The research portfolio also includes studies of targeted biologic therapies for asthma, especially for patients with frequent symptoms or severe inflammatory disease. These trials are designed to test whether newer medicines can offer stronger and longer-lasting benefit than current options.

  • Biologic treatment strategies
  • Severe asthma management
  • Comparing new targeted therapies with established care

This area highlights a broader move toward more precise respiratory research that matches therapy to the underlying disease pattern.

05 Inflammation Markers and Asthma Control

Another important focus is the study of markers that reflect airway inflammation in asthma. By observing changes such as FeNO, researchers can better understand how well a treatment is affecting the underlying disease process.

  • Fraction of exhaled nitric oxide (FeNO)
  • Uncontrolled asthma
  • Evaluating whether new therapy can reduce airway inflammation

This kind of research helps improve both diagnosis and treatment monitoring in respiratory tract disease care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.